Member Info for neilrich3

My favourite part...The Company expects to launch its LFT in Q2 2021, slightly later than planned as it has taken the strategic decision to develop a next generation of LFT to detect the neutralizing antibodies generated by successful immunisation and, therefore, to assist in monitoring the effectiveness of future vaccines3. The Company believes this exemplifies how it can extend the revenue horizon for COVID-19 as the demand for testing continues to evolve

Can't imagine the shareholders shall have an opportunity during the Q&A Friday, I think that the event shall be very carefully controlled, any questions restricted to important customers only, although I might be wrong!

Should there be something that requires an announcement, NCYT won't have a choice I'd expect any news to be released immediately, not a question of waiting for the current volatility to settle, NCYT are not saving up items of News for an appropriate moment.

Dartron, I agree, we already know that the DHSC UK Government contract has clauses which prevent NCYT from publicising the on going progress with the contract. More than likely that GM & co are busy negotiating a massive 3 year deal, a contract so big that it shall dwarf what was previously disclosed, obviously they're not in a position to provide shareholders with a running commentary.

....and so the PR company goes running to the competitor and spills the beans?! I'm sorry, but these are professional companies, there shall be strict confidentiality agreements. There's no issue!

The PR company handles the PR, they're not in a position to leak company secrets or details on patents.

If not working with NCYT, which other company would it likely be? Too much of a coincidence that NCYT is already ahead of the curve, sounds good and has to be worth a few hundred million from the UK alone.

....and yet Greggs (loss making and trading at x48 prospective earnings) is up more than 3%. Jet2 (their 2021 program is a write off) up 5%!!

Unbelievable, just don't understand this market.

Wasn't blown away by the PMs announcement, unfortunately a long road out of lockdown with considerable risks along the way and that's just the UK.

...and why is NCYT down, can't see any earnings issues upon the horizon.

SteveV. Yes, unless I missed something obvious, surge testing is most certainly using PCR, positive PCR tests being sent away for sequencing.

Don't think that any phase 2 shall be as previously envisaged, care homes for instance, information from the government yesterday states that all care home staff shall have a PCR test once a week, the tests shall be collected by a courier therefore not point of care.

Certainly envisage an extension to phase 1, I think that pillar 1 testing shall continue for years.

However Prof Pea**** says the lack of equity for sequencing data is an area of equal concern. With the notable exceptions of Denmark, which has the capacity to map 10,000 cases a week, and South Africa, others are lagging well behind.

It was reported last month that Germany has so far sequenced about 3,400 cases in the entire pandemic (although it has since published a draft government order requiring five per cent of all samples from positive tests to be sent for genome testing). According to an article published this month in the British Medical Journal, the US currently sequences fewer than one per cent of new samples while many countries, especially in Africa, currently have no genome sequencing at all.

“I’m very concerned about it,” Prof Pea**** says of the lack of international effort, describing developing world countries with limited access to vaccines, no sequencing data and partial natural immunity to the virus as “a biological melting point for evolution and escaped mutants”. It is then only a matter of time before those new variants re-infect the world.
https://www.telegraph.co.uk/health-fitness/body/meet-worlds-top-covid-variant-hunter-used-work-corner-shop/

Professor Sharon Pea****’s team at Cog-UK is leading the world in identifying mutant Covid strains – now the rest must catch up https://www.telegraph.co.uk/health-fitness/body/meet-worlds-top-covid-variant-hunter-used-work-corner-shop/

For all we know they might have had ten resignations in recent weeks....just saying.

Interesting that there's no mention of Halo within the article about AZN testing their workforce whilst trialling the new test. Perhaps far more to do with Novacyt than Halo, or jointly developed and therefore equal share.

HALO™ is a British biotech enterprise that offers a cheaper, more sensitive and faster saliva-based virus testing system to get business back to work as the world recovers from the COVID-19 crisis.

As well as a more effective test, the HALO system integrates an encrypted verification app and advanced logistics in a complete business solution.

The HALO team is led by EpiPen inventor Craig Rochford PhD alongside biotech and computer scientists from Oxford University. HALO is already working with a number of professional services, transport and other organisations. https://www.haloverify.com

Perhaps HALO would be a suitable bolt on acquisition?

Let's not get carried away, did we not have a lovely swing last week....which within 24 hours was reversed.

He'd could not have been more open about phase one, written into the contract that NCYT are not allowed to publicise or disclose details with regards to progress made. Fortunately we can check the UK Gov pillar 1 data and clearly pillar 1 capacity has been ramped up since October, this past week has seen 200k capacity a day.

From 15th February 2021, all international arrivals in quarantine are required to take a test on or before day 2 (of their quarantine period), for variant surveillance, and a test on or after day 8 (of their quarantine period).

The provider should ensure test manufacturers are providing data to the MHRA demonstrating the suitability of the device for identifying SARS-CoV-2 Variants of Concern.

SNPSig?